KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Gross Margin (2016 - 2025)

Supernus Pharmaceuticals has reported Gross Margin over the past 13 years, most recently at 89.13% for Q4 2025.

  • Quarterly Gross Margin rose 411.0% to 89.13% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 89.63% through Dec 2025, up 140.0% year-over-year, with the annual reading at 89.63% for FY2025, 140.0% up from the prior year.
  • Gross Margin was 89.13% for Q4 2025 at Supernus Pharmaceuticals, down from 90.13% in the prior quarter.
  • Over five years, Gross Margin peaked at 90.13% in Q3 2025 and troughed at 82.29% in Q2 2021.
  • The 5-year median for Gross Margin is 88.15% (2023), against an average of 87.6%.
  • Year-over-year, Gross Margin plummeted -1109bps in 2021 and then surged 568bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 89.32% in 2021, then fell by -3bps to 86.28% in 2022, then rose by 2bps to 88.06% in 2023, then dropped by -3bps to 85.01% in 2024, then grew by 5bps to 89.13% in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Gross Margin are 89.13% (Q4 2025), 90.13% (Q3 2025), and 89.83% (Q2 2025).